Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:HOOD.O News 24 January 2026

Robinhood stock in focus after hours as “Retail Kings” ETF debut collides with Fed week ahead

Robinhood stock in focus after hours as “Retail Kings” ETF debut collides with Fed week ahead

Robinhood shares rose 0.7% to $106.99 in after-hours trading Friday, with volume near 17.6 million shares. The new Defiance Retail Kings ETF launched with Robinhood among its initial holdings. Investors are watching for the Fed’s Jan. 27-28 meeting and Robinhood’s Feb. 10 earnings report. Peers ended mixed, with Coinbase down 2.8% and Interactive Brokers up 0.5%.
24 January 2026
······

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop